Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.
Minerva Gastroenterol Dietol
; 66(2): 172-176, 2020 Jun.
Article
in English
| MEDLINE | ID: covidwho-7667
ABSTRACT
The outbreak of SARS-CoV-2 disease (COVID-19) is currently, March 2020, affecting more than 100,000 people worldwide and, according to the WHO (World Health Organization), a pandemic is shortly expected. The virus infects the lower respiratory tract and causes severe pneumonia and mortality in approximately 10% and 3-5%, respectively, of cases, mainly among the elderly and/or people affected by other diseases. AHCC is an α-glucan-based standardized mushroom extract that has been extensively investigated as an immunostimulant both in animals and/or in humans affected by West Nile virus, influenza virus, avian influenza virus, hepatitis C virus, papillomavirus, herpes virus, hepatitis B virus and HIV by promoting a regulated and protective immune response. Although the efficacy of AHCC has not yet been specifically evaluated with respect to SARS-CoV-2 disease, its action in promoting a protective response to a wide range of viral infections, and the current absence of effective vaccines, could support its use in the prevention of diseases provoked by human pathogenic coronavirus, including COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Polysaccharides
/
Adjuvants, Immunologic
/
Coronavirus Infections
/
Shiitake Mushrooms
/
Betacoronavirus
Type of study:
Experimental Studies
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Minerva Gastroenterol Dietol
Journal subject:
Nutritional Sciences
/
Gastroenterology
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS